AbbVie (ABBV) Fair Value & DCF

ABBV$293.89+0.58 +0.20%
Market cap$519.48BEnterprise value$591.13BRevenue (TTM)$66.01BMarket positionTop 5%

ABBV fair value $420.39. Price $293.89. Price is 30% below fair value.

Worked example

Cash-flow value. Starting free cash flow is $10.68 a share. Year 1 is the first earnings forecast, so it has no growth rate of its own. The forecast then reaches 6.81%, and that pace fades in a straight line to 3% terminal growth by year 10. The discount rate is 8.70% (beta 0.80). It is beta-adjusted and capped at 12%. The cash-flow value is $406.09 a share.

Earnings value. Next-twelve-months earnings per share of $15.77 times 27.56 is $434.68. The peer group is Drug Manufacturers - General, 10 companies worth at least $10 billion. Peer median 28.0. Own 10-year median 27.1. The multiple used is the average of the two, kept between 8 and 30, which is 27.56.

Fair value is the average of the two, $420.39. The price is $293.89, which is 30.1% below fair value.

AbbVie (ABBV) Fair Value & DCF

ABBV price $293.89 +0.58 +0.20%

Ticker
ABBV
Price
$293.89
Change
+0.58 +0.20%
Market cap
$519.48B
P/E
50.08
Forward P/E
18.59
Dividend yield
2.35%
Beta
0.28
Sector
Healthcare
Industry
Drug Manufacturers - General
Stocklytics score
56
Value
35
Quality
73
Growth
59

Stocklytics score rationale: value 35, quality 73, growth 59.

AI Score 70. AbbVie Inc. has a strong market capitalization of $505.4 billion and a solid gross profit margin of approximately 76.3%

Summary

AbbVie Inc. operates in the Healthcare sector and Drug Manufacturers - General industry. The company reports a net margin of 15.7% and a dividend yield of 2.4%.

Valuation

The shares trade at a P/E ratio of 50.6, which is a key valuation input but cannot be assessed against peers or history from the provided facts. Price-to-book is -88.0, limiting its usefulness as a conventional valuation measure.

Quality

A net margin of 15.7% indicates the company generated positive reported profitability. The negative price-to-book figure of -88.0 suggests book-value-based analysis requires caution.

Growth

No revenue, earnings-growth, estimate-revision, or price-trend data is provided. Growth cannot be evaluated from the available facts.

Risks

The P/E ratio of 50.6 may leave the shares sensitive to changes in earnings expectations. Negative price-to-book of -88.0 also makes balance-sheet valuation interpretation less straightforward.

Fair value

ABBV fair value $420.39. Price $293.89. Price is 30% below fair value.

Below fair value, around its usual discount.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price.

Fair value blends a 10-year DCF and an earnings multiple: the average of the DCF value and an earnings value from next-twelve-months EPS times 27.6, a blend of the Drug Manufacturers - General median (28.0) and the stock's own 10-year median (27.1). How we calculate it →

Compare ABBV

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2027-02-03—3.89—18.34B
2026-10-303.823.7317.40B17.32B
2026-07-313.653.6116.99B16.80B
2026-04-292.652.5915.00B14.72B
2026-02-042.712.6516.62B16.41B
2025-10-311.861.7715.78B15.59B
2025-07-312.972.8815.42B15.03B
2025-04-252.462.3813.34B12.93B
2025-01-312.162.9815.10B14.83B
2024-10-303.002.9214.46B14.28B
2024-07-252.652.5714.46B14.02B
2024-04-262.312.2612.31B11.93B
2024-02-022.792.7614.30B12.98B
2023-10-272.952.8613.93B13.67B
2023-07-272.912.7913.87B13.52B
2023-04-272.462.4412.22B12.17B
2023-02-093.603.5415.12B15.33B
2022-10-283.663.5614.81B14.96B
2022-07-293.373.3114.58B14.66B
2022-04-293.243.1413.54B13.61B
2022-02-023.313.2914.89B14.95B
2021-10-293.333.2314.34B14.35B
2021-07-303.113.1113.96B13.96B
2021-04-302.952.7713.01B12.81B
2021-02-032.922.8513.86B13.73B
2020-10-302.832.7512.90B12.63B
2020-07-312.342.2410.43B9.76B
2020-05-012.422.258.62B8.01B
2020-02-072.212.198.70B8.63B
2019-11-012.332.298.48B8.37B
2019-07-262.262.218.26B8.07B
2019-04-252.142.057.83B7.50B
2019-01-251.901.928.30B8.48B
2018-11-022.142.028.24B7.77B
2018-07-272.001.988.28B8.15B
2018-04-261.871.797.93B7.59B
2018-01-261.481.447.74B7.53B
2017-10-271.411.397.00B6.90B
2017-07-281.421.406.94B6.85B
2017-04-271.281.266.54B6.44B

Dividends

Yield 2.35%. Payout ratio 117.28%. Frequency Quarterly.

Safety score 68/100 · Moderate. Payout ratio is 117% of earnings, above what earnings cover. Dividends use a moderate share of free cash flow. Dividends were paid in 15 separate years. Yield is 2.4%, in a range that is usually sustainable.

Ex-dateDividendRecordPaymentFrequency
2027-01-15$1.822027-01-152027-02-16Quarterly
2026-10-15$1.732026-10-152026-11-16Quarterly
2026-07-15$1.732026-07-152026-08-14Quarterly
2026-04-15$1.732026-04-152026-05-15Quarterly
2026-01-16$1.732026-01-162026-02-17Quarterly
2025-10-15$1.642025-10-152025-11-14Quarterly
2025-07-15$1.642025-07-152025-08-15Quarterly
2025-04-15$1.642025-04-152025-05-15Quarterly
2025-01-15$1.642025-01-152025-02-14Quarterly
2024-10-15$1.552024-10-152024-11-15Quarterly
2024-07-15$1.552024-07-152024-08-15Quarterly
2024-04-12$1.552024-04-152024-05-15Quarterly
2024-01-12$1.552024-01-162024-02-15Quarterly
2023-10-12$1.482023-10-132023-11-15Quarterly
2023-07-13$1.482023-07-142023-08-15Quarterly
2023-04-13$1.482023-04-142023-05-15Quarterly
2023-01-12$1.482023-01-132023-02-15Quarterly
2022-10-13$1.412022-10-142022-11-15Quarterly
2022-07-14$1.412022-07-152022-08-15Quarterly
2022-04-13$1.412022-04-152022-05-16Quarterly
2022-01-13$1.412022-01-142022-02-15Quarterly
2021-10-14$1.302021-10-152021-11-15Quarterly
2021-07-14$1.302021-07-152021-08-16Quarterly
2021-04-14$1.302021-04-152021-05-14Quarterly
2021-01-14$1.302021-01-152021-02-16Quarterly
2020-10-14$1.182020-10-152020-11-16Quarterly
2020-07-14$1.182020-07-152020-08-14Quarterly
2020-04-14$1.182020-04-152020-05-15Quarterly
2020-01-14$1.182020-01-152020-02-14Quarterly
2019-10-11$1.072019-10-152019-11-15Quarterly
2019-07-12$1.072019-07-152019-08-15Quarterly
2019-04-12$1.072019-04-152019-05-15Quarterly
2019-01-14$1.072019-01-152019-02-15Quarterly
2018-10-12$0.962018-10-152018-11-15Quarterly
2018-07-12$0.962018-07-132018-08-15Quarterly
2018-04-12$0.962018-04-132018-05-15Quarterly
2018-01-11$0.712018-01-122018-02-15Quarterly
2017-10-12$0.642017-10-132017-11-15Quarterly
2017-07-12$0.642017-07-112017-08-15Quarterly
2017-04-11$0.642017-04-132017-05-15Quarterly
2017-01-11$0.642017-01-132017-02-15Quarterly
2016-10-12$0.572016-10-142016-11-15Quarterly
2016-07-13$0.572016-07-152016-08-15Quarterly
2016-04-13$0.572016-04-152016-05-16Quarterly
2016-01-13$0.572016-01-152016-02-16Quarterly
2015-10-13$0.512015-10-152015-11-16Quarterly
2015-07-13$0.512015-07-152015-08-14Quarterly
2015-04-13$0.512015-04-152015-05-15Quarterly
2015-01-13$0.492015-01-152015-02-13Quarterly
2014-10-10$0.422014-10-152014-11-17Quarterly
2014-07-11$0.422014-07-152014-08-15Quarterly
2014-04-11$0.422014-04-152014-05-15Quarterly
2014-01-13$0.402014-01-152014-02-14Quarterly
2013-10-10$0.402013-10-152013-11-15Quarterly
2013-07-11$0.402013-07-152013-08-15Quarterly
2013-04-11$0.402013-04-152013-05-15Quarterly
2013-01-11$0.402013-01-152013-02-15Quarterly

Insider trades

DateInsiderActionSharesPriceValue
2026-10-14Carethers JohnOther0——
2026-09-30Quaggin Susan EBuy59$261.5915.43K
2026-09-30RAPP EDWARD JBuy129$261.5933.75K
2026-08-14Donoghoe NicholasBuy32.71K$79.022.58M
2026-08-14Donoghoe NicholasSell32.71K$250.008.18M
2026-08-14Donoghoe NicholasSell32.71K$79.022.58M
2026-06-30RAPP EDWARD JBuy134$251.6433.72K
2026-06-30Quaggin Susan EBuy62$251.6415.60K
2026-05-08FALK THOMAS JBuy1.12K——
2026-05-08WADDELL FREDERICK HBuy1.12K——
2026-05-08Roberts Rebecca BBuy1.12K——
2026-05-08RAPP EDWARD JBuy1.12K——
2026-05-08Quaggin Susan EBuy1.12K——
2026-05-08MEYER MELODY BBuy1.12K——
2026-05-08Hart Brett JBuy1.12K——
2026-05-08FREYMAN THOMAS CBuy1.12K——
2026-05-08Davis Jennifer L.Buy1.12K——
2026-05-08BURNSIDE WILLIAM H.L.Buy1.12K——
2026-05-08AUSTIN ROXANNE SBuy1.12K——
2026-03-31Quaggin Susan EBuy71$217.4915.44K
2026-03-31RAPP EDWARD JBuy155$217.4933.71K
2026-03-31Alpern Robert JBuy35$217.497.61K
2026-03-04Purdue David RyanSell5.23K$233.561.22M
2026-03-02Siatis Perry CSell5.78K$233.511.35M
2026-03-02Siatis Perry CSell10.29K$234.662.41M
2026-03-02Siatis Perry CSell2.60K$235.26611.68K
2026-02-27Purdue David RyanSell2.11K$232.08489.22K
2026-02-27Crum Demetris DSell1.59K$232.08369.94K
2026-02-27Thakkar RoopalSell8.04K$232.081.87M
2026-02-27Michael Robert A.Sell36.52K$232.088.48M
2026-02-27Stewart Jeffrey RyanSell23.81K$232.085.53M
2026-02-27Siatis Perry CSell14.85K$232.083.45M
2026-02-27Reents Scott TSell21.64K$232.085.02M
2026-02-27SALEKI-GERHARDT AZITASell16.31K$232.083.78M
2026-02-27Purdue David RyanSell2.69K$232.08624.76K
2026-02-27Donoghoe NicholasSell12.87K$232.082.99M
2026-02-25Siatis Perry CBuy7.29K$192.861.41M
2026-02-25Siatis Perry CBuy7.78K$175.281.36M
2026-02-25Siatis Perry CBuy7.31K$149.621.09M
2026-02-25Siatis Perry CSell22.38K$230.005.15M
2026-02-25Siatis Perry CSell7.29K$192.861.41M
2026-02-25Siatis Perry CSell7.78K$175.281.36M
2026-02-25Siatis Perry CSell7.31K$149.621.09M
2026-02-18Thakkar RoopalBuy6.64K——
2026-02-18Thakkar RoopalBuy3.35K——
2026-02-18Thakkar RoopalBuy2.14K——
2026-02-18Thakkar RoopalBuy6.01K——
2026-02-18Thakkar RoopalBuy21.94K$230.045.05M
2026-02-18Purdue David RyanBuy1.38K——
2026-02-18Purdue David RyanBuy1.29K——
2026-02-18Purdue David RyanBuy890——
2026-02-18Purdue David RyanBuy2.50K——
2026-02-18Purdue David RyanBuy4.88K$230.041.12M
2026-02-18Stewart Jeffrey RyanBuy8.99K——
2026-02-18Stewart Jeffrey RyanBuy9.43K——
2026-02-18Stewart Jeffrey RyanBuy9.27K——
2026-02-18Stewart Jeffrey RyanBuy26.06K——
2026-02-18Stewart Jeffrey RyanBuy26.81K$230.046.17M
2026-02-18Siatis Perry CBuy5.81K——
2026-02-18Siatis Perry CBuy5.63K——
2026-02-18Siatis Perry CBuy5.79K——
2026-02-18Siatis Perry CBuy16.29K——
2026-02-18Siatis Perry CBuy19.50K$230.044.49M
2026-02-18SALEKI-GERHARDT AZITABuy6.64K——
2026-02-18SALEKI-GERHARDT AZITABuy7.07K——
2026-02-18SALEKI-GERHARDT AZITABuy6.06K——
2026-02-18SALEKI-GERHARDT AZITABuy17.04K——
2026-02-18SALEKI-GERHARDT AZITABuy20.31K$230.044.67M
2026-02-18Crum Demetris DBuy13.41K$230.043.08M
2026-02-18Crum Demetris DBuy1.24K——
2026-02-18Crum Demetris DBuy1.22K——
2026-02-18Donoghoe NicholasBuy6.22K——
2026-02-18Donoghoe NicholasBuy5.17K——
2026-02-18Donoghoe NicholasBuy4.63K——
2026-02-18Donoghoe NicholasBuy13.03K——
2026-02-18Donoghoe NicholasBuy20.31K$230.044.67M
2026-02-18Reents Scott TBuy7.26K——
2026-02-18Reents Scott TBuy7.61K——
2026-02-18Reents Scott TBuy8.91K——
2026-02-18Reents Scott TBuy25.06K——
2026-02-18Reents Scott TBuy21.94K$230.045.05M
2026-02-18Michael Robert A.Buy22.12K——
2026-02-18Michael Robert A.Buy14.45K——
2026-02-18Michael Robert A.Buy12.03K——
2026-02-18Michael Robert A.Buy33.83K——
2026-02-18Michael Robert A.Buy81.25K$230.0418.69M
2025-12-31Alpern Robert JBuy34$228.497.77K
2025-12-31Quaggin Susan EBuy68$228.4915.54K
2025-12-31RAPP EDWARD JBuy147$228.4933.59K
2025-09-30Quaggin Susan EBuy67$231.5415.51K
2025-09-30Alpern Robert JBuy33$231.547.64K
2025-09-30RAPP EDWARD JBuy145$231.5433.57K
2025-08-12SALEKI-GERHARDT AZITABuy42.37K$54.862.32M
2025-08-12SALEKI-GERHARDT AZITASell42.37K$198.428.41M
2025-08-12SALEKI-GERHARDT AZITASell42.37K$54.862.32M
2025-08-05Donoghoe NicholasSell3.23K$198.27641.24K
2025-08-05Donoghoe NicholasSell10.06K$198.592.00M
2025-07-01Crum Demetris DOther0——
2025-07-01Crum Demetris DOther0$175.280
2025-07-01Crum Demetris DOther0$192.860

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 4.35K, holders +130 vs prior quarter. Ownership 76.07%.

HolderSharesChangeChange %Value
BLACKROCK, INC.149.49M-1.21M-0.80%37.62B
VANGUARD CAPITAL MANAGEMENT LLC115.40M515.77K+0.45%29.04B
STATE STREET CORP82.60M1.38M+1.70%20.78B
VANGUARD PORTFOLIO MANAGEMENT LLC48.48M-1.05M-2.11%12.20B
JPMORGAN CHASE & CO47.86M-8.88M-15.65%12.17B
GEODE CAPITAL MANAGEMENT, LLC47.00M260.85K+0.56%11.81B
MORGAN STANLEY38.90M884.23K+2.33%9.79B
CAPITAL RESEARCH GLOBAL INVESTORS30.10M-1.15M-3.69%7.57B
NORGES BANK25.55M25.55MNew6.43B
BANK OF AMERICA CORP /DE/21.24M-2.70M-11.28%5.34B
FMR LLC20.77M-988.92K-4.54%5.23B
NORTHERN TRUST CORP20.56M-652.93K-3.08%5.17B
FRANKLIN TEMPLETON INC19.93M5.37M+36.92%5.01B
CAPITAL WORLD INVESTORS19.18M3.34M+21.07%4.83B
GOLDMAN SACHS GROUP INC16.29M1.15M+7.57%4.10B
CAPITAL INTERNATIONAL INVESTORS15.64M1.22M+8.46%3.94B
PRICE T ROWE ASSOCIATES INC /MD/14.75M1.75M+13.42%3.71B
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC14.27M106.09K+0.75%3.59B
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P.12.91M12.91MNew3.25B
CHARLES SCHWAB INVESTMENT MANAGEMENT INC12.91M-53.17K-0.41%3.25B
BANK OF NEW YORK MELLON CORP12.85M-424.79K-3.20%3.23B
UBS GROUP AG12.85M-1.21M-8.58%3.23B
LEGAL & GENERAL GROUP PLC11.55M-611.37K-5.03%2.91B
AMERIPRISE FINANCIAL INC11.52M451.20K+4.08%2.90B
DEUTSCHE BANK AG\10.77M1.24M+13.03%2.71B

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener